B‐chronic lymphocytic leukaemia patients with stable benign disease show a distinctive membrane phenotype
- 1 April 1984
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 56 (4), 655-660
- https://doi.org/10.1111/j.1365-2141.1984.tb02189.x
Abstract
Summary. The circulating B cells of 98 patients with B-CLL were analysed with a panel of conventional markers and monoclonal antibodies including RFA-1 and RFA-4. A subgroup of patients was defined with a distinctive double membrane marker phenotype (RFA-1+, RFA-4+). These patients showed features of clinical stability. Their physical signs, haematological features and lymphocyte counts remained unchanged for 5–10 years: therefore, the RFA-1+, RFA-4+ membrane phenotype appears to identify a subgroup of B-CLL patients with a particularly non-progressive disease.This publication has 6 references indexed in Scilit:
- Normal equivalent cells of B cell malignancies: analysis with monoclonal antibodiesBritish Journal of Haematology, 1983
- 3 The normal and malignant germinal centreClinics in Haematology, 1982
- Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia.The Journal of Experimental Medicine, 1982
- Monoclonal antibodies recognizing normal human T lymphocytes and malignant human B lymphocytes: a comparative study.The Journal of Immunology, 1981
- Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7Blood, 1981
- Clinical staging of chronic lymphocytic leukemiaBlood, 1975